Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement - Wikidata - awgldk - TriplyDB

Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement

Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement

http://www.wikidata.org/entity/Q33622648

about

Secondary treatment of acute graft-versus-host disease: a critical review Prognostic value of response after upfront therapy for acute GVHD Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial.Steroid-Refractory Acute GVHD: Predictors and Outcomes.Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation.Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease.Six-month freedom from treatment failure is an important end point for acute GVHD clinical trials Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins.Adult adherent stromal cells in the management of graft-versus-host disease.Mesenchymal stromal cells: potential roles in graft-versus-host disease prophylaxis and treatment.Ex Vivo CD34+-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Di Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome.Long-term follow-up of corticosteroid refractory acute GVHD treated with an Inolimomab-based algorithm: a single center experience.Dismal response to high-dose methylprednisolone after failure to respond to standard dose in patients with acute GVHD.Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis.Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective study.

P2860

Q26823275-8B021C0F-1346-422B-A0D9-5380A532F4C3 Q33964701-29F5FA29-B379-4891-99D7-2E83AAD5F12D Q34666851-DC026E67-6EF7-4967-BAF1-05580BCE9BA5 Q35082549-9F0D1E35-E3BE-4670-A262-819FF7EEDBCF Q35550596-B5898680-132D-4DE1-8ECB-E2A3C3B1F80D Q35748508-C5BA68DE-71CF-4B8F-A68F-594118569B9F Q37113099-303D8C4A-49F9-46F2-9051-C90A9BC872EB Q37552088-E30B401E-B022-4BA0-90C3-84C0E63280D2 Q37624271-F49BD0F2-0F21-4985-891D-8FFD65EA1AA8 Q37810286-280296CF-5679-48C1-8717-1C35DE85D187 Q38176442-E35BDC10-B2F7-4F3D-A48E-4060205AD6F3 Q38808411-791E1A17-511C-44CD-81BA-0399029DB45B Q40407930-AD76C666-19E1-4A3C-BFE7-1A9F48F295B5 Q41290373-B6F8627A-5A5C-450C-A166-C2FF6AA1FFF1 Q42270601-888DA4F7-6AED-4B99-822B-7C994A3476E8 Q43140213-AE07BD38-26C5-44A6-AA48-8BC07CE9CE3C Q44005585-D9125D5C-BAA5-4E31-B301-88B75342DE3D Q55319551-32A8FEAB-5BAD-415C-95B8-95D80976C840

P2860

Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement

http://www.wikidata.org/entity/Q33622648

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Endpoints for clinical trials ...... ost disease: a joint statement

@ast

Endpoints for clinical trials ...... ost disease: a joint statement

@en

type

label

Endpoints for clinical trials ...... ost disease: a joint statement

@ast

Endpoints for clinical trials ...... ost disease: a joint statement

@en

prefLabel

Endpoints for clinical trials ...... ost disease: a joint statement

@ast

Endpoints for clinical trials ...... ost disease: a joint statement

@en

P1433

Q33622648-AD680710-03C1-42E5-8D4C-6D92B4ABDD66

P1476

Q33622648-9BA48CCD-4A4B-4CFC-A452-32C13B84A908

P2093

Q33622648-06FCAFB2-BF37-40A8-A85A-A33A3AA6AF8C

Q33622648-22BB6435-43A6-4A77-899A-9395ECBC8187

Q33622648-252D76C5-A74F-4D8D-948F-4C89E79DDB10

Q33622648-357E12E9-6DCC-4BEB-93AA-8D4141D8053E

Q33622648-4CB12495-F12E-475D-8D06-583B341506D6

Q33622648-786E41D8-F3E1-4736-8C9B-95F1CBDEEBDA

Q33622648-7A947111-C616-4298-B12F-18FCD52A0898

Q33622648-7F77898C-50A0-4DFD-B02C-1246DA0604BC

Q33622648-92B56737-FCF6-40FC-BD54-891496ECDFFD

Q33622648-ACC25F08-2533-4536-A332-8CD5B8F5C210

P2860

Q33622648-02F0F8F2-39D1-4655-997D-FEF77CED934F

Q33622648-0DDA1C0F-E591-4FAF-BF3F-A2E5DFF13075

Q33622648-0F7B961A-6871-43FA-B913-25375D467933

Q33622648-12E093D2-3A2A-4C04-BD16-3AE91E42B995

Q33622648-19556934-70DF-4F92-B6E4-6B3CBABB7BF6

Q33622648-237C6F75-9396-4264-B2F1-32BD34CF7B8E

Q33622648-24EA19E8-7A8C-485E-86F2-70276887603C

Q33622648-31849E5D-7D07-4E67-834A-1046CCB3A195

Q33622648-36B3E3FD-1970-4F65-8D29-C9355236B5F6

Q33622648-3C338F40-1D31-4962-90D5-E2E9B87507B0

P304

Q33622648-4B2522F7-46B9-473E-B4E0-A375F90B5DDE

P31

Q33622648-EAF0C883-2B9D-4988-87EF-5E7E18894F56

P356

Q33622648-518CD790-B9D4-4729-B470-1A9EFC9EAB31

P433

Q33622648-1065B829-C46E-4437-AF67-885F0BA6B447

P478

Q33622648-8B1104F6-3757-4368-8CAE-9CA817BE121B

P577

Q33622648-5BF5A292-5BF7-4645-8C94-4A8B9C8CBBFE

P5875

Q33622648-DFCF091D-15B1-4041-80CA-438BB91A2C1A

P698

Q33622648-C21CCB0A-4D25-470F-8C5B-C454C03575B5

P932

Q33622648-899A94E9-D215-4FDB-9BAF-476C2CC75FFA

P356

J.BBMT.2009.03.012

P1433

Biology of Blood and Marrow Transplantation

P1476

Endpoints for clinical trials ...... ost disease: a joint statement

@en

P2093

Carlos R Bachier

http://www.w3.org/2001/XMLSchema#string

Daniel Weisdorf

http://www.w3.org/2001/XMLSchema#string

Elizabeth J Shpall

http://www.w3.org/2001/XMLSchema#string

Hans-Georg Klingemann

http://www.w3.org/2001/XMLSchema#string

Joseph P Uberti

http://www.w3.org/2001/XMLSchema#string

Margaret L Macmillan

http://www.w3.org/2001/XMLSchema#string

Michael W Schuster

http://www.w3.org/2001/XMLSchema#string

Nelson J Chao

http://www.w3.org/2001/XMLSchema#string

Partow Kebriaei

http://www.w3.org/2001/XMLSchema#string

Paul J Martin

http://www.w3.org/2001/XMLSchema#string

P2860

Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study

A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease

Review article: efficacy of infliximab in Crohn's disease--induction and maintenance of remission.

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

International uniform response criteria for multiple myeloma.

New approaches for preventing and treating chronic graft-versus-host disease.

Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR

Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation.

Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report.

Pitfalls in the design of clinical trials for prevention or treatment of acute graft-versus-host disease.

P304

777-784

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBMT.2009.03.012

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26304016

http://www.w3.org/2001/XMLSchema#string

P698

19539208

http://www.w3.org/2001/XMLSchema#string

P932

2814363

http://www.w3.org/2001/XMLSchema#string